Strides Pharma Science today announced its partnership with Medicines Patent Pool (MPP) to commercialize molnupiravir in the international markets.
Strides and its subsidiary, Universal Corporation (Kenya), have entered into a voluntary non?]exclusive sub?]license partnership with MPP covering 105 countries as part of MSD (NYSE: MRK, a trading name of Merck & Co., Inc, Kenilworth, NJ, USA) and MPP?fs partnership to enable a global reach for molnupiravir. Strides and UCL will manufacture the product at their WHO PQ facilities in India and Nairobi, Kenya. UCL owns and operates one of the two WHO PQ facilities in the Sub?]Saharan region.
In December 2021, Strides received Emergency Use Authorization (EUA) from the DCGI to launch molnupiravir 200mg in India (under the brand name StripiravirTM). Besides the 200mg strength, Strides has also developed and manufactured molnupiravir in 400mg, which significantly benefits the patients by reducing the pill burden and ensuring better compliance.
Powered by Capital Market - Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.